Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT07319949

Evaluating the Predictive Capability of Transcriptomic Profiling for Identifying the Primary Site of Metastatic Tumors

Evaluative Study on Predicting the Primary Site of Metastatic Tumors Using Transcriptomic Profiling for Tumor Tissue Origin Identification

Status
Not Yet Recruiting
Phase
Study type
Observational
Enrollment
30 (estimated)
Sponsor
Fudan University · Academic / Other
Sex
All
Age
Healthy volunteers
Not accepted

Summary

This study will enroll patients with metastatic malignancies. Tumor samples (fresh or formalin-fixed paraffin-embedded tissue specimens) will undergo RNA extraction and next-generation sequencing (RNA-seq). Once the raw data is obtained, the system will analyze the transcriptomic feature values (cancer-specific RNA transcripts and tissue-specific RNA transcripts) expressed in the tumor tissue samples to further predict tissue origin using a machine learning model. The output includes probabilities and confidence intervals for tissue origin.

Detailed description

This is a non-interventional, observational study. Through a single-center, prospective clinical trial, the study aims to utilize the transcriptomic profiling for tumor tissue origin identification to predict the tissue origin of primary sites in metastatic tumors and evaluate the accuracy and specificity of this prediction solution. Primary Endpoint: The accuracy of the transcriptomic profiling for tumor tissue origin identification in predicting the primary site of metastatic tumors (expressed as overall accuracy with its 95% confidence interval). Secondary Endpoints: 1. The specificity and sensitivity of the transcriptomic profiling for tumor tissue origin identification in predicting the primary site of metastatic tumors. 2. Exploratory analysis of characteristic molecular markers expressed in metastatic lesions from different primary sites.

Conditions

Timeline

Start date
2026-01-15
Primary completion
2026-10-13
Completion
2026-10-13
First posted
2026-01-06
Last updated
2026-01-06

Source: ClinicalTrials.gov record NCT07319949. Inclusion in this directory is not an endorsement.